Mazdutide dosage chart
10 mg Vial
Mazdutide is dosed at 2.5 mg–5 mg weekly via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (standard protocol).
- Typical weekly range
- 2.5–5 mg once weekly with gradual titration.
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing schedule
| Week | Weekly Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg (2,500 mcg) | 75 units (0.75 mL) |
| Weeks 5–8+ | 5 mg (5,000 mcg) | 150 units (1.50 mL) |
Reconstitution Steps
| Week | Weekly Dose | Units (per injection) (mL) | Notes |
|---|---|---|---|
| Weeks 1–4 | 5 mg (5,000 mcg) | 100 units (1.00 mL) | 0.5 vials |
| Weeks 5–8 | 7.5 mg (7,500 mcg) | 150 units (1.50 mL) | 0.75 vials |
| Weeks 9–12+ | 10 mg (10,000 mcg) | 200 units (2.00 mL) | 1 vial |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl until dissolved (do not shake vigorously).
- 4Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
Practical considerations for safe and effective administration.
- Use a new sterile insulin syringe for each weekly injection; dispose in a proper sharps container.
- Rotate injection sites weekly (abdomen, thighs, upper arms) to minimize local irritation and lipoatrophy.
- For doses requiring >3 mL volume, split into two separate injections at different sites for comfort and absorption.
- Allow reconstituted vials to reach room temperature before withdrawing dose to reduce viscosity.
- Document dose, injection site, and any side effects to track response and optimize protocol.
How This Works
Mazdutide functions as a dual agonist at both GLP‑1 and glucagon receptors, combining the appetite‑suppressing and glucose‑lowering effects of GLP‑1 with the energy‑expenditure benefits of glucagon activation. This dual mechanism distinguishes it from single‑target GLP‑1 agonists and has shown robust weight loss efficacy in clinical trials. Phase 2 studies demonstrated 6.7–11.3% body weight reduction at 3–6 mg weekly doses over 24 weeks. A 48‑week phase 3 trial reported sustained weight loss of 11–14% with 4–6 mg weekly maintenance. In type 2 diabetes populations, mazdutide achieved meaningful HbA1c reductions (~1.7%) alongside ~7% weight loss. The extended half‑life enables convenient once‑weekly dosing with steady pharmacologic exposure.
Potential Benefits & Side Effects
Observations from clinical trial evidence.
- Significant body weight reduction (6–14% over 24–48 weeks) in obesity trials.
- Meaningful HbA1c improvement (~1.7% reduction) in type 2 diabetes populations.
- Favorable metabolic effects including improved lipid profiles and glucose control.
- Convenient once‑weekly dosing improves adherence compared to daily regimens.
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common adverse events, typically mild‑to‑moderate and diminishing with continued use.
- Injection‑site reactions (redness, swelling, mild discomfort) may occur; rotate sites to minimize.
- Gradual dose titration significantly improves tolerability and reduces discontinuation rates.
Lifestyle Factors
Complementary strategies for optimal outcomes.
- Maintain a balanced, nutrient‑dense diet with adequate protein to support lean mass during weight loss.
- Combine regular resistance training with aerobic exercise to preserve muscle and enhance metabolic adaptations.
- Prioritize consistent sleep (7–9 hours nightly) and stress management to support adherence and hormonal balance.
- Stay well‑hydrated and monitor electrolyte intake, especially during initial titration when GI effects may be present.
Injection Technique
Subcutaneous injection guidance based on clinical best practices.
- Clean the vial stopper and injection site with alcohol swabs; allow to air‑dry completely.
- Use aseptic technique: wipe stoppers, use sterile needles, and avoid touching needle tip.
- Pinch a skinfold and insert the needle at 45–90° into subcutaneous fatty tissue (not muscle).
- Do not aspirate for subcutaneous injections; inject slowly and steadily over 5–10 seconds.
- Withdraw needle and apply gentle pressure with a clean swab; do not rub vigorously.
- Rotate injection sites systematically: abdomen (at least 2 inches from navel), front/outer thighs, or outer upper arms.
- For volumes >3 mL, divide dose into two injections at separate sites for comfort and absorption.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Mazdutide is an investigational peptide not approved for prescription use in most countries (as of 2025, it has received initial approval in China for obesity treatment). All information is provided for research and educational purposes only. Consult qualified healthcare professionals before considering any peptide protocol.
Mazdutide dosage FAQs
How much bacteriostatic water do you use to reconstitute Mazdutide?
Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (standard protocol). for a 10 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the Mazdutide dosing schedule look like?
Weeks 1–4 — 2.5 mg (2,500 mcg) — 75 units (0.75 mL); Weeks 5–8+ — 5 mg (5,000 mcg) — 150 units (1.50 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for Mazdutide?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl until dissolved (do not shake vigorously).
How should reconstituted Mazdutide be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..
How many insulin syringe units equal a Mazdutide dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is Mazdutide approved for human use?
No. Mazdutide is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.